ZyVet Animal Health, a leader in affordable generic pharmaceuticals for companion animals and a wholly owned subsidiary of Zydus Pharmaceuticals (USA), has announced the launch of the first FDA-approved generic phenylpropanolamine hydrochloride tablets. This product provides veterinarians and pet owners with a trusted and cost-effective treatment for managing urinary incontinence in dogs, a condition that significantly impacts the well-being of pets and their families.
This milestone reflects ZyVet’s commitment to its core mission: delivering safe, effective, and accessible therapies that help veterinary professionals provide high-quality care without financial barriers.
Addressing an Important Medical Need in Companion Animals
Phenylpropanolamine hydrochloride has long been recognized as a frontline therapy for treating urinary incontinence caused by urethral sphincter hypotonus. This condition is especially common in spayed female dogs and aging canines, often leading to unintentional urine leakage, discomfort, and stress for both pets and their owners. Left untreated, the condition can disrupt the pet–family bond and reduce overall quality of life.
By offering a reliable generic alternative, ZyVet enables veterinarians to confidently prescribe a clinically proven therapy while supporting improved long-term treatment adherence. The tablets are available in multiple strengths to ensure accurate dosing and flexibility, meeting the varied needs of small, medium, and large-breed dogs.
Leadership Statement
Commenting on the launch, Punit Patel, President and CEO of Zydus Americas, said:
“Urinary incontinence can be a source of frustration for pet owners and a quality-of-life issue for dogs. With our phenylpropanolamine hydrochloride tablets, we’re delivering a solution that combines clinical reliability with affordability. This ensures veterinarians can treat more patients effectively while helping clients remain consistent with therapy. At ZyVet, we firmly believe that innovation doesn’t always require a premium price tag. Every pet deserves access to high-quality, compassionate care—and every veterinarian deserves confidence in the tools they prescribe.”
Strengthening the Case for Veterinary Generics
ZyVet’s latest launch comes at a pivotal time in the animal health industry. Currently, fewer than 20% of FDA-approved animal drugs have a generic version, leaving a significant gap in affordable options for veterinarians and pet owners. By addressing this gap, ZyVet is reshaping perceptions of generic medicines in animal health—demonstrating that they are not only equally effective and safe as branded products, but also vital to expanding access to care.
With its rapid portfolio expansion, ZyVet is driving a paradigm shift: ensuring that more essential veterinary therapies become available in generic form, reducing treatment costs without compromising quality.
Backed by Zydus Lifesciences’ Global Expertise
As part of Zydus Lifesciences, ZyVet benefits from more than 70 years of expertise in pharmaceutical research, development, regulatory compliance, and manufacturing. This legacy empowers ZyVet to maintain the highest standards of quality assurance, quality control, and production scalability, ensuring consistent supply and reliable performance across its portfolio.
Looking Ahead
The launch of phenylpropanolamine hydrochloride tablets not only strengthens ZyVet’s position as a leader in the underserved generics market but also reaffirms its broader mission: to make high-quality, evidence-based veterinary treatments accessible and affordable for all. By bridging the gap between medical innovation and affordability, ZyVet is enabling veterinarians to provide better care to more patients—improving outcomes, strengthening the human–animal bond, and supporting healthier communities.
